Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 9 Next > Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia October 19, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations October 18, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer October 15, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021 October 14, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia October 01, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization September 27, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19 September 22, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021 September 20, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status September 16, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study September 16, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy September 13, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conference September 01, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options August 19, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program August 03, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Second Quarter 2021 Financial Results July 29, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD July 19, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers BNTX GILD New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor July 17, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults July 17, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021 July 15, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research July 12, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options June 28, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma June 28, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks June 24, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China June 23, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets June 21, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021 June 21, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies June 17, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C June 10, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation June 04, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study June 04, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.